ACE-031 (soluble ActRIIB-IgG1 Fc fusion protein)
ACE-031, ActRIIB-Fc, soluble activin receptor type IIB, sActRIIB-Fc, ActRIIB-IgG1, ramatercept (proposed INN; not independently confirmed in this audit)
ACE-031 was a decoy receptor: the muscle-side portion of ActRIIB, fused to an antibody tail, designed to mop up myostatin and related proteins before they could reach the real receptor. It worked, producing measurable lean mass gains in healthy volunteers within a month. Development was stopped anyway, when boys with Duchenne muscular dystrophy in the follow-on trial began having nosebleeds and developing dilated small blood vessels.
Mechanism
ACE-031 is a ligand trap, not a receptor antagonist in the classical sense. It presents the extracellular ligand-binding domain of activin receptor type IIB in a soluble, dimeric, Fc-stabilised form, so that circulating ActRIIB ligands bind to it and are sequestered away from cell-surface receptors. The Fc portion serves two functions: it dimerises the receptor ectodomain, matching the natural stoichiometry of ligand engagement, and it confers a multi-week half-life through neonatal Fc receptor recycling.
The ligands captured include myostatin (GDF-8), activin A, activin B, GDF-11 and several BMPs. Blocking them prevents assembly of the ActRIIB with ALK4/ALK5 signalling complex, abolishing SMAD2/3 phosphorylation in muscle. The downstream consequence is the mirror image of myostatin signalling: relief of SMAD3-mediated AKT inhibition, reduced FoxO-driven transcription of MuRF1 and atrogin-1, restored myogenic transcription and satellite cell activation, and net accretion of contractile protein.
The breadth is deliberate and it is why ACE-031 was more potent than any selective anti-myostatin antibody. Lee's 2005 work had already shown that soluble ActRIIB produces large muscle mass gains in mice within two weeks and remains partially active in myostatin-null animals, because it removes several ligands at once. That same breadth is why it failed. Activin A and the BMPs it also traps are essential regulators of vascular endothelial integrity, bone remodelling and haematopoiesis. The bleeding and telangiectasia observed in the Duchenne trial were not idiosyncratic toxicity but the predictable consequence of blocking a receptor family that does far more than restrain muscle, a pattern later echoed by the bleeding and haematological warnings on sotatercept, the ActRIIA-Fc fusion approved for pulmonary arterial hypertension.
What the research shows
The Phase 1 data were unambiguous on the pharmacology. Attie and colleagues randomised 48 healthy postmenopausal women to a single subcutaneous dose of ACE-031 (0.02 to 3 mg/kg) or placebo. At the highest dose, day 29 showed a 3.3% increase in total body lean mass by DXA (p = 0.03) and a 5.1% increase in thigh muscle volume by MRI (p = 0.03). Half-life was 10-15 days with linear kinetics, and the main adverse event was injection-site erythema. A single subcutaneous injection producing a measurable, imaging-confirmed increase in muscle volume within a month is a genuinely notable result and explains the enthusiasm around the programme. A second Phase 1 study in 70 postmenopausal women (NCT00952887) was also completed.
The Phase 2 programme in Duchenne muscular dystrophy is the important part of the story. Campbell and colleagues reported a randomised, double-blind, placebo-controlled ascending-dose trial in ambulatory boys, given subcutaneously, with an open-label extension. There was a trend toward maintenance of six-minute walk distance in the ACE-031 groups against a decline in placebo, but the published report is explicit that this was not statistically significant. Lean mass and bone mineral density increased and fat mass fell. The trial was stopped after the second dosing regimen. The reason was not a serious or severe adverse event but a pattern of potential safety concerns: epistaxis and telangiectasias, small-vessel effects appearing in a paediatric population. Both the main study (NCT01099761, 24 enrolled) and its extension (NCT01239758, 11 enrolled) are recorded as terminated on ClinicalTrials.gov, and development was discontinued.
The preclinical literature has since caught up with what the clinical signal implied. Relizani and colleagues reported in 2014 that ActRIIB blockade triggered muscle fatigability and a metabolic myopathy, a direct warning that the mass added by this mechanism is not straightforwardly functional muscle. Other work found improved bone mass and strength with soluble ActRIIB in a Duchenne mouse model, so the pathway's effects are genuinely multi-tissue in both directions.
The honest summary is that ACE-031 proved the pharmacology and then proved the problem with it. It remains the reference example for why receptor-level blockade of the activin pathway is more powerful and more dangerous than ligand-selective blockade, a lesson that shaped the design of every subsequent programme, including apitegromab, which binds only the pro- and latent forms of myostatin.
Evidence assessment
Mixed evidence
Two completed randomised placebo-controlled Phase 1 trials showed clear pharmacodynamic effects, but the Phase 2 programme in Duchenne muscular dystrophy was terminated early for safety, leaving efficacy unresolved and total human exposure small and short.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers Mixed evidence
At the highest dose, day 29 total body lean mass rose 3.3% by DXA (p=0.03) and thigh muscle volume 5.1% by MRI (p=0.03); mean terminal half-life 10-15 days with linear kinetics; tolerability generally favourable with adverse events dominated by injection-site erythema.
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial Mixed evidence
A trend toward maintenance of six-minute walk distance versus decline on placebo was observed but was not statistically significant, alongside trends for increased lean mass and bone mineral density and reduced fat mass; the study was stopped over potential safety concerns of epistaxis and telangiectasias.
Regulation of muscle growth by multiple ligands signaling through activin type II receptors Preclinical only
Soluble ActRIIB produced large increases in muscle mass within two weeks and remained partially active in myostatin-null mice, establishing that the decoy-receptor approach captures ligands beyond myostatin.
Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy Preclinical only
Muscle enlarged by ActRIIB blockade showed increased fatigability and features of metabolic myopathy, indicating that added mass does not equate to added function.
Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy Preclinical only
Soluble ActRIIB improved bone mass and mechanical strength, consistent with the bone mineral density increases observed in the human Duchenne trial.
Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control Limited evidence
Established a combined liquid chromatography high-resolution tandem mass spectrometry method capable of detecting this drug class in human doping-control samples.
Safety
ACE-031's safety record is the reason it is remembered. Across the Phase 1 studies in healthy postmenopausal women, tolerability was generally favourable and adverse events were dominated by injection-site erythema, with no dose-limiting toxicity identified over the 0.02 to 3 mg/kg single-dose range.
The signal emerged in patients. In ambulatory boys with Duchenne muscular dystrophy receiving repeated subcutaneous dosing, investigators observed epistaxis and telangiectasias, dilated small vessels visible in skin and mucosa, along with reports of gum bleeding. The published report describes these as potential safety concerns rather than serious or severe adverse events, and that nuance matters: the study was stopped on the basis of a mechanistically coherent pattern in a paediatric population, not because anyone was gravely harmed. It was a cautious decision and, in retrospect, a well-founded one. Activin and BMP signalling through activin type II receptors is integral to vascular endothelial homeostasis, and blocking it broadly has consequences for small-vessel integrity.
Subsequent experience with the same receptor family supports that reading. Sotatercept, an ActRIIA-Fc fusion approved in 2024 for pulmonary arterial hypertension, carries labelled warnings for erythrocytosis, severe thrombocytopenia and serious bleeding events, with epistaxis among its common adverse reactions. The pattern is consistent enough to be treated as a class effect of broad activin receptor blockade rather than a quirk of one molecule.
Two further points. First, immunogenicity: Fc-fusion proteins can elicit anti-drug antibodies, and for a decoy receptor these could in principle cross-react with the native receptor. Second, and specific to the muscle question: the mass gained by blocking this pathway may not be fully functional, given preclinical evidence of fatigability and metabolic myopathy in hypertrophied muscle.
ACE-031 is not available in any form. It is a mammalian-cell-expressed glycosylated Fc-fusion protein that cannot be synthesised as a peptide, and no legitimate supply exists outside the terminated clinical programme. Any product sold under this name should be assumed not to be ACE-031.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation and no current clinical trial authorisation. As a recombinant Fc-fusion protein it would be a biological medicinal product requiring full authorisation; supply for human use outside that route breaches the Human Medicines Regulations 2012. Not controlled under the Misuse of Drugs Act 1971. |
| United States | Never approved by FDA for any indication. Developed by Acceleron Pharma in partnership with Shire under an investigational new drug application; the Phase 2 Duchenne programme (NCT01099761) and its extension (NCT01239758) are recorded as terminated on ClinicalTrials.gov and development was discontinued. Two Phase 1 studies in healthy postmenopausal women (NCT00755638, 48 enrolled; NCT00952887, 70 enrolled) are recorded as completed. No marketing application was ever filed. Not DEA-scheduled. The related ActRIIA-Fc fusion sotatercept was approved in March 2024 for pulmonary arterial hypertension, so the receptor family, though not this molecule, now has an approved representative. |
| WADA (sport) | Prohibited at all times. The WADA Prohibited List, section S4.3 (Agents preventing activin receptor IIB activation), names ACE-031 explicitly as the example of a decoy activin receptor. Substances in S4.3 are Specified Substances. A combined LC-HRMS/MS method for detecting inhibitors of activin receptor signalling pathways in doping-control samples was published in 2025 (Sakellariou et al.). |
Questions
Because boys with Duchenne muscular dystrophy receiving it developed epistaxis and telangiectasias, nosebleeds and dilated small blood vessels, along with reports of gum bleeding. The publication describes these as potential safety concerns rather than serious or severe adverse events, but the pattern was mechanistically coherent: the activin type II receptors that ACE-031 blocks are important for small-vessel integrity, not just for muscle. The sponsor terminated the Phase 2 trial and its extension and discontinued development. Later warnings for bleeding and erythrocytosis on sotatercept, a related ActRIIA-Fc fusion, suggest this is a class effect.
Yes, and quickly. In a randomised placebo-controlled Phase 1 study of 48 healthy postmenopausal women, a single subcutaneous dose at the highest level produced a 3.3% increase in total body lean mass by DXA and a 5.1% increase in thigh muscle volume by MRI at day 29, both statistically significant. That is real, imaging-confirmed pharmacodynamic activity. Whether it would have translated into functional benefit was never established: in the Duchenne trial the walking-distance trend favoured ACE-031 but did not reach statistical significance, and the study was terminated before completion.
No. ACE-031 is a glycosylated Fc-fusion protein of around 76-80 kDa produced in mammalian cell culture. It cannot be made by peptide synthesis, and no legitimate supply exists outside the terminated clinical programme, which ended over a decade ago. Any product offered under this name should be assumed not to be ACE-031. It is also named explicitly on the WADA Prohibited List as the example of a decoy activin receptor.
ACE-031 blocked at the receptor, trapping myostatin, activin A and B, GDF-11 and several BMPs together, which made it more powerful but also removed signals the vasculature and bone marrow need. Apitegromab is an antibody that binds only the pro- and latent forms of myostatin, leaving activin signalling intact. That selectivity makes it weaker but far better tolerated, and it is the design that finally produced a positive Phase 3 result, in spinal muscular atrophy. ACE-031's failure is a large part of why the field moved toward selectivity.